Clinical Trials for PYC Therapeutics

Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy

A Study of Two Doses of VP-001 Administered Intravitreally in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy Previously Treated with VP001

Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003

SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Natural History of PRPF31 Mutation-Associated Retinal Dystrophy